Gut–Adipose Tissue Axis and Metabolic Health
Open Access
- 6 June 2025
- journal article
- review article
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 47 (6) , 424
Abstract
The gut–adipose tissue axis plays a crucial role in metabolic health. It is a two-way communication pathway between the gastrointestinal tract and adipose tissue. This axis influences physiological processes vital for maintaining metabolic health, including energy homeostasis, lipid metabolism, and inflammation. Emerging research suggests that the gut microbiota, composed of trillions of microorganisms residing in the intestines, significantly impacts this axis by modulating host metabolism. An imbalance in the gut microbiota (dysbiosis) has been linked to obesity, insulin resistance, and other metabolic disorders. Innovative therapeutic strategies and dietary interventions aimed at modulating the gut–adipose tissue axis have shown encouraging results in improving metabolic health. A deeper critical understanding of the gut–adipose tissue axis is, therefore, essential in understanding the pathophysiology of metabolic disorders so that targeted interventions can be developed to prevent and treat these metabolic disorders. This article highlights the need for integrative approaches that consider both gastrointestinal and adipose functions in metabolic health management.Keywords
All Related Versions
This publication has 102 references indexed in Scilit:
- Impact of bariatric surgery on gut microbiota in obese patients: A systematic reviewIndian Journal of Gastroenterology, 2025
- Sleeve Gastrectomy and Gastric Bypass Impact in Patient’s Metabolic, Gut Microbiome, and Immuno-inflammatory Profiles—A Comparative StudyObesity Surgery, 2025
- The gut microbiota and diabetes: research, translation, and clinical applications – 2023 Diabetes, Diabetes Care, and Diabetologia Expert ForumDiabetologia, 2024
- Gut Microbes in Polycystic Ovary Syndrome and Associated Comorbidities; Type 2 Diabetes, Non-Alcoholic Fatty Liver Disease (NAFLD), Cardiovascular Disease (CVD), and the Potential of Microbial TherapeuticsProbiotics and Antimicrobial Proteins, 2024
- Therapeutic Effects of Butyrate on Pediatric ObesityJAMA Network Open, 2022
- Obesity I: Overview and molecular and biochemical mechanismsBiochemical Pharmacology, 2022
- Host genetic control of gut microbiome compositionMammalian Genome, 2021
- Microbiota issue in CKD: how promising are gut-targeted approaches?Journal Of Nephrology, 2018
- Intestine farnesoid X receptor agonist and the gut microbiota activate G‐protein bile acid receptor‐1 signaling to improve metabolismHepatology, 2018
- Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled studyDiabetologia, 2011